January 6, 2017
BMS tries out GeneCentric’s Cancer Subtype Platform for Opdivo clinical trials
Bristol-Myers Squibb (BMS) and GeneCentric Diagnostics have teamed up to explore the possibility of GeneCentric’s Cancer Subtype Platform (CSP) could identify translational biomakers for Opdivo, that could help for future clinical trials.